Vascular Training Grant

这是耶鲁大学血管研究博士后T32的第四次竞争性续签申请。的 到目前为止，已完成培训的研究员中，65%获得了学术教职和/或职业生涯 科学方面，许多人获得了独立的拨款支持，这是项目成功的有力指标。这个 持续的目标是为高素质、多样化的内科医生提供实验室和翻译研究培训 (医学博士和医学博士/博士学位)和血管生物学博士后研究员，为以下职业做准备 血管生物学和医学相关学科的独立调查人员。实习生的选择将是 基于对血管生物学的承诺和较强的以前的研究经验或潜力。 将鼓励临床和基础科学系的申请，并在全国范围内竞争 7个年度时段。少数族裔申请者将通过多种途径专门征集。目前的38% 资金周期研究员是代表不足的少数族裔。培训将以导师为基础，还包括 咨询委员会和说教课程。培训的最短期限为2年。这个 心血管医学部和耶鲁大学血管生物学和治疗学跨学科项目 将是该计划的基础。一项关键资产是耶鲁大学在血管生物学领域的跨学科优势。 参与教职的院系包括心血管内科、免疫生物学、 药理学、病理学、遗传学、生物工程、生理学、心胸外科和计算学 科学。教师的选择是基于令人印象深刻的导师历史，正在进行的血管研究 高效率，强大的外部支持，并致力于担任项目内的导师。举例 研究机会包括：(1)白细胞-内皮细胞的分子决定因素和后果 (2)利用核成像和磁共振成像研究血管生成和血管重塑的分子成像 在动物模型中；(3)定位和鉴定与血管发育有关的基因 人类疾病(动静脉畸形、冠状动脉疾病)；(4)血管工程 生物材料；(5)用于临床试验的血管生成基因调节剂的产生；(6)新型单细胞RNA 序列分析方法测定促进动脉粥样硬化的细胞表型。最后一个 这些代表了新加入我们计划的顶级计算科学部分。这是一个很宽的 与疾病相关的血管研究的范围，以及关键的翻译组件。实习生的进步将是 由每位导师、学员的顾问委员会和项目联席主任监督。它是 期望我们将培训未来的国内和国际血管研究领先者。心血管病 疾病是美国的主要死亡原因，也是世界范围内死亡的主要原因。这一计划将 为来自多个学科的不同个人提供重要机会，最终引领高影响力 努力减少心血管疾病的发病率，改善心血管疾病的结局。

This is the fourth competing renewal application for Yale University’s Vascular Research Postdoctoral T32. Of fellows who have completed training to date, 65% have obtained academic faculty positions and/or careers in science, and many have received independent grant support, strong indicators of program success. The continued goal is to provide laboratory and translational research training for highly qualified, diverse physician (M.D. and M.D./Ph.D.) and Ph.D. postdoctoral fellows in vascular biology, in preparation for careers as independent investigators in blood vessel biology- and medicine-related disciplines. Trainee selection will be based on a commitment to vascular biology and strong prior research experience or potential of same. Applications will be encouraged from clinical and basic science departments, with a nationwide competition for 7 yearly slots. Minority applicants will be specifically solicited through numerous avenues. 38% of the current funding cycle fellows are underrepresented minorities. The training will be mentor-based, also including advisory committees and didactic courses. The minimum duration of training will be 2 years. The Cardiovascular Medicine Division and Yale’s Interdisciplinary Program in Vascular Biology and Therapeutics will be the foundations for the program. A key asset is Yale’s interdisciplinary strength in vascular biology. Departmental affiliations for participating faculty include Cardiovascular Medicine, Immunobiology, Pharmacology, Pathology, Genetics, Bioengineering, Physiology, Cardiothoracic Surgery, and Computational Science. Faculty were chosen based on impressive histories of mentorship, ongoing vascular research productivity, strong extramural support and commitment to serve as mentors within the program. Examples of research opportunities include: (1) molecular determinants and consequences of leukocyte-endothelial cell interactions; (2) molecular imaging of angiogenesis and vascular remodeling utilizing nuclear and MR imaging in animal models; (3) mapping and identification of genes that contribute to the development of vascular disease (arterio-venous malformation, coronary artery disease) in humans; (4) engineering of vascular biomaterials; (5) generation of angiogenic gene regulators for use in clinical trials and (6) novel single cell RNA sequence analytic methods for determination of atherosclerosis-promoting cellular phenotypes. The last of these represents a top tier computational science component newly added to our program. This is a wide range of disease-related vascular research, with key translational components. Trainee progress will be monitored by each mentor, the trainee’s advisory committee and the Program Co-Directors. It is the expectation that we will train future national and international leaders in vascular research. Cardiovascular disease is the leading cause of death in the U.S., and a major cause of mortality world-wide. This program will provide important opportunities for diverse individuals from multiple disciplines to eventually lead high impact efforts at reducing the incidence of, and improving outcomes in, cardiovascular disease.